Paper · 42542997
FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.
Xue L and 14 others. Target Oncol, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials. Papers, record 42542997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42542997
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Fibroblast Growth Factors | Major topic |
| Head and Neck Neoplasms | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Receptors, Fibroblast Growth Factor | Major topic |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Receptor, Fibroblast Growth Factor, Type 1 |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| PW2023A-11 | Shanghai Pudong New Area Health Commission | PubMed | ||
| Y-Young2024-0414 | Beijing Xisike Clinical Oncology Research Foundation | PubMed |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT03758664 | Clinical Study of ICP-192 in Solid Tumors Patients | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT05372120 | A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations | Derived from the trial | Yes | ClinicalTrials.gov |
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27,718,784 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718784 | PubMed |
| 2 | 34,562,395 | Head and neck cancer. | Lancet | 2021 | https://conductscience.org/library/papers/34562395 | PubMed |
| 3 | 38,572,751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 4 | 35,003,900 | Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. | Oncoimmunology | 2022 | https://conductscience.org/library/papers/35003900 | PubMed |
| 5 | 38,378,518 | Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome. | Mol Cancer | 2024 | https://conductscience.org/library/papers/38378518 | PubMed |
| 6 | 26,096,068 | Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells. | J Pathol | 2015 | https://conductscience.org/library/papers/26096068 | PubMed |
| 7 | 36,646,686 | Targeted therapy for head and neck cancer: signaling pathways and clinical studies. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36646686 | PubMed |
| 8 | 33,417,831 | Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. | Cancer Cell | 2021 | https://conductscience.org/library/papers/33417831 | PubMed |
| 9 | 31,679,945 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. | Lancet | 2019 | https://conductscience.org/library/papers/31679945 | PubMed |
| 10 | 35,176,457 | FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. | Ann Oncol | 2022 | https://conductscience.org/library/papers/35176457 | PubMed |
1 to 10 of 41
See all 41 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CCND1 | 595 | PubTator's text mining | https://conductscience.org/library/genes/595 |
Source NCBI Gene
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42542997
GET https://conductscience.org/api/papers/v1/42542997/references?page=2